
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Policy· June 10, 2026 · 9 min read

Policy· June 10, 2026 · 10 min read
Inside 20 million FAERS reports: 57% serious, Enbrel leads, death in 1.9 million
By Ran Chen#FDA Approval#Drug Pricing#Clinical Evidence

Approvals· June 10, 2026 · 10 min read
The FDA approval engine: 29,135 applications, 78% generics, and a BLA surge
By Ran Chen#FDA Approval#Generic Entry#Biosimilars

Policy· June 10, 2026 · 9 min read
What's in short supply: 1,146 shortages, two-thirds injectable, and an anesthesia crisis
By Ran Chen#Supply Chain#FDA Approval#Drug Pricing

Approvals· June 10, 2026 · 10 min read
What the EU approves: 2,313 medicines, 29% oncology, 28 biosimilars in 2024

Pipeline· June 8, 2026 · 11 min read
Botulinum toxin biosimilar pathway: the 351(k) race to challenge Botox
By Ran Chen#Biosimilars#FDA Approval#BLA Approval

Approvals· June 8, 2026 · 9 min read
FDA drug-device combination product pathway: PMOA and launch strategy

Global· June 8, 2026 · 11 min read
South Korea MFDS biosimilar reform 2026: what US launch teams need to know
By Ran Chen#Biosimilars#Regulatory#FDA Approval

Pipeline· June 8, 2026 · 10 min read
Veterinary JAK inhibitors Apoquel to Numelvi: FDA pathway compared

Pipeline· June 7, 2026 · 9 min read
Cytisinicline smoking cessation PDUFA preview: first new pharmacotherapy in 20 years
By Ran Chen#PDUFA Date#FDA Approval#Clinical Evidence